-
article
Tanase MG, Djilani L, Lamontagne R, Derbel R, Baril M, Roy V, Blais M, Buteau FA, Khuong HT, Gros-Louis F, Leclerc M, Dupre N
Utility of 18F-FDG PET/CT in the Surveillance of Patients With Neurofibromatosis Type 1
Neurol Genet
12 (2), 2026.
-
article
Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É and Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM
Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases t…
Can Urol Assoc J
20 (6), 2026.
-
article
Zamanian A, Rousseau É and Buteau FA, Arsenault F, Beaulieu A, April G, Juneau D, Plouznikoff N, Turcotte ÉE, Allard C, Richard PO, Saad F, Guérin B, Pouliot F, Beauregard JM
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
Cancer Imaging
25 (1), 2025.
